← All trials
NCT07210996
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2025
- Primary completion
- Oct 6, 2025
- Completion date
- Oct 16, 2025
- First posted
- Oct 7, 2025
- Last posted
- Nov 26, 2025
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abbisko Therapeutics Co, LtdLead sponsor
- Jinlin UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.